SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis

Arnold, A; Cooke, GS; Kon, OM; Dedicoat, M; Lipman, M; Loyse, A; Ster, IC; Harrison, TS (2017) Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother, 61 (9). e02586-16. ISSN 1098-6596 https://doi.org/10.1128/AAC.02586-16
SGUL Authors: Harrison, Thomas Stephen Chis Ster, Delizia Irina

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (1MB) | Preview

Abstract

Background: The prolonged use of injectable agents in an MDR-TB regimen is recommended by the WHO despite association with ototoxicity and nephrotoxicity.Objective: We undertook this study to look at the relative adverse effects of capreomycin and amikacin.Methods: We reviewed the case notes of 100 consecutive patients treated at 4 MDR-TB treatment centres in the UK.Results: The median total duration of treatment with an injectable agent was 178 (IQR 109-192, n=73) days for those with MDR-TB, 179 (104-192, n=12) days for those with MDR-TB plus fluoroquinolone resistance and 558 (324-735, n=8) days for those with XDR-TB. Injectable use was longer for those started with capreomycin at 183 (IQR 123-197) days compared to 119 (IQR 83-177) days with amikacin (p=0.002). Excluding XDR-TB, 51 (51/85, 60%) patients were treated with an injectable for over 6 months and 12 (12/85, 14%) for over 8 months. 40 % of all patients discontinued the injectable due to hearing loss. 55% of patients experienced ototoxicity: 5 times (hazard ratio (HR) 5.2, CI 1.2-22.6, p=0.03) more likely in those started on amikacin compared to treatment with capreomycin only. Amikacin was associated with less hypokalemia than capreomycin (Odds ratios: 0.28 (0.11-0.72)), with 5 (5/37, 14%) patients stopping capreomycin due to recurrent electrolyte loss. There was no difference in the number experiencing a creatinine rise of > 1.5 times baseline.Conclusion: Hearing loss is frequent in this cohort, though significantly lower in those starting capreomycin which should be given greater consideration as a first line agent.

Item Type: Article
Additional Information: Copyright © 2017 American Society for Microbiology. This is the accepted version of an article published in final form at http://doi.org/10.1128/AAC.02586-16
Keywords: Microbiology, 0605 Microbiology, 1108 Medical Microbiology, 1115 Pharmacology And Pharmaceutical Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Antimicrob Agents Chemother
ISSN: 1098-6596
Language: eng
Dates:
DateEvent
September 2017Published
10 July 2017Published Online
9 June 2017Accepted
Publisher License: Publisher's own licence
PubMed ID: 28696239
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/108981
Publisher's version: https://doi.org/10.1128/AAC.02586-16

Actions (login required)

Edit Item Edit Item